SIS Shulov Innovative Science Overview
Shulov Innovative Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on developing New Chemical Entities (NCE’s) for a variety of therapeutic uses. The NCE’s are short synthetic peptides with a unique pharmacological activity of combined potency as an effective anti-inflammatory, anti-viral, and analgesic agent. The NCE’s under development are short synthetic peptides branded as ZEP-3 and ZEP-4, and both molecules possess the unique biological activity and potent therapeutic use for a wide range of clinical indications. The company completed a Phase II clinical study in Herpes Labialis (Cold sores) and has approached the FDA in preparation for a pre-IND meeting to secure an IND submission for an advanced Phase III clinical trial in Herpes Labialis patients in the US. It is the next step towards regulatory approval for the marketing and commercialization of its lead compound. In addition, SIS conducts a Phase II clinical study in Atopic Dermatitis (AD), a common and underserved dermatological disorder, in 9 clinical sites at the leading dermatology departments at hospitals and community clinics in Israel. SIS is developing additional clinical indications such as Herpes Zoster, Genital Herpes, Burns, and Lung Inflammation. Pre-clinical work is complete, and the company is ready to start a Phase I/II study on each of these indications.
Latest News
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | sis-shulov.com |
Locations
Prof. Hillel ve-Khanan Oppenheimer Street 10, Rehovot, Israel
Photos & Videos
No files yet
SIS Shulov Innovative Science Business
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (7)
pain-reliefskin-carebiopharmaceuticaltargeted-therapydermatologyanti-inflammatorytopical-treatmentGeographic Markets
United StatesIsraelSIS Shulov Innovative Science Financials
SIS Shulov Innovative Science Lifecycle
SIS Shulov Innovative Science News
1 articleSIS Shulov Innovative Science Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 31 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
SIS Shulov Innovative Science Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 96/100 |
| Missing | video or image, funding rounds, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 511084519 |
| Crunchbase | sis-shulov-innovative-science |
| Phone | +97289314114 |
| Creator | Ophir Shahaf |
| Creator email | ophir@sis-shulov.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-06-07T00:00:00.000Z |
| Created | 2019-03-10T00:00:00.000Z |
| Claimed | Yes |